Announcement PDF Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity Race Oncology Limited ABN 61 149 318 749 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Daniel Tillett Date of last notice 25 November 2025 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. N/A Date of change 26 November 2025 No. of securities held prior to change 17,738,160 fully paid ordinary shares 2,448,342 options exercisable at $1.25, expiring 29/5/2026 1,534,712 options exercisable at $1.45, expiring 29/11/2028 3,061,101 options exercisable at $4.25, expiring 29/11/2028 432,680 options exercisable at $1.67, expiring 30/6/2029 Class Fully paid ordinary shares Number acquired 22,000 Number disposed - Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 2 Value/Consideration includes brokerage/gst Note: If consideration is non-cash, provide details and estimated valuation $58,744.03 No. of securities held after change 17,760,160 fully paid ordinary shares 2,448,342 options exercisable at $1.25, expiring 29/5/2026 1,534,712 options exercisable at $1.45, expiring 29/11/2028 3,061,101 options exercisable at $4.25, expiring 29/11/2028 432,680 options exercisable at $1.67, expiring 30/6/2029 Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back On-market purchase. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed N/A Interest acquired N/A Interest disposed N/A Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation N/A Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No If so, was prior written clearance provided to allow the trade to proceed during this period? N/A If prior written clearance was provided, on what date was this provided? N/A